DocuSign, Inc. (NASDAQ:DOCU) Shares Sold by Mediolanum International Funds Ltd

Mediolanum International Funds Ltd trimmed its stake in DocuSign, Inc. (NASDAQ:DOCU - Free Report) by 5.4% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 126,748 shares of the company's stock after selling 7,302 shares during the period. Mediolanum International Funds Ltd owned about 0.06% of DocuSign worth $7,804,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in DOCU. E. Ohman J or Asset Management AB acquired a new stake in shares of DocuSign in the third quarter valued at $186,000. Global Trust Asset Management LLC increased its stake in DocuSign by 117.6% during the third quarter. Global Trust Asset Management LLC now owns 2,368 shares of the company's stock worth $147,000 after purchasing an additional 1,280 shares during the period. International Assets Investment Management LLC lifted its position in shares of DocuSign by 5,660.8% during the third quarter. International Assets Investment Management LLC now owns 438,914 shares of the company's stock worth $27,252,000 after purchasing an additional 431,295 shares in the last quarter. Lecap Asset Management Ltd. grew its holdings in shares of DocuSign by 312.3% in the third quarter. Lecap Asset Management Ltd. now owns 52,858 shares of the company's stock valued at $3,282,000 after purchasing an additional 40,037 shares in the last quarter. Finally, Castleview Partners LLC lifted its holdings in DocuSign by 4,530.0% during the 3rd quarter. Castleview Partners LLC now owns 1,389 shares of the company's stock worth $86,000 after buying an additional 1,359 shares in the last quarter. 77.64% of the stock is currently owned by institutional investors and hedge funds.

DocuSign Stock Performance

DOCU stock traded down $1.59 during trading on Friday, hitting $68.99. The stock had a trading volume of 2,564,023 shares, compared to its average volume of 2,933,302. DocuSign, Inc. has a 1-year low of $38.11 and a 1-year high of $73.80. The stock has a market cap of $14.12 billion, a price-to-earnings ratio of 132.67, a price-to-earnings-growth ratio of 7.33 and a beta of 0.92. The company's 50 day moving average price is $61.87 and its two-hundred day moving average price is $57.66.

DocuSign (NASDAQ:DOCU - Get Free Report) last posted its quarterly earnings data on Thursday, September 5th. The company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.80 by $0.17. DocuSign had a return on equity of 16.18% and a net margin of 34.56%. The business had revenue of $736.03 million for the quarter, compared to analysts' expectations of $727.20 million. During the same quarter last year, the firm earned $0.09 earnings per share. The business's revenue was up 7.0% on a year-over-year basis. As a group, sell-side analysts forecast that DocuSign, Inc. will post 1.01 earnings per share for the current fiscal year.

Insider Buying and Selling

In other DocuSign news, Director Daniel D. Springer sold 287,052 shares of the company's stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $53.78, for a total transaction of $15,437,656.56. Following the completion of the sale, the director now directly owns 923,445 shares in the company, valued at $49,662,872.10. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, Director Daniel D. Springer sold 287,052 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $53.78, for a total value of $15,437,656.56. Following the completion of the sale, the director now owns 923,445 shares in the company, valued at approximately $49,662,872.10. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Daniel D. Springer sold 70,983 shares of the business's stock in a transaction on Monday, August 5th. The stock was sold at an average price of $49.84, for a total transaction of $3,537,792.72. Following the completion of the transaction, the director now owns 891,373 shares in the company, valued at $44,426,030.32. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 427,554 shares of company stock valued at $23,129,150. Insiders own 1.66% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. JMP Securities reiterated a "market outperform" rating and issued a $84.00 target price on shares of DocuSign in a report on Thursday, September 5th. Royal Bank of Canada lifted their price objective on shares of DocuSign from $52.00 to $57.00 and gave the stock a "sector perform" rating in a research report on Friday, September 6th. Bank of America raised their target price on DocuSign from $60.00 to $68.00 and gave the stock a "neutral" rating in a research report on Friday, September 6th. Wells Fargo & Company upped their target price on shares of DocuSign from $48.00 to $50.00 and gave the company an "underweight" rating in a report on Friday, September 6th. Finally, Citigroup upped their price target on shares of DocuSign from $86.00 to $87.00 and gave the company a "buy" rating in a research report on Friday, September 6th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $63.40.

DocuSign Profile

DocuSign, Inc provides electronic signature solution in the United States and internationally. The company provides e-signature solution that enables sending and signing of agreements on various devices; Contract Lifecycle Management (CLM), which automates workflows across the entire agreement process; Document Generation streamlines the process of generating new, custom agreements; and Gen for Salesforce, which allows sales representatives to automatically generate agreements with a few clicks from within Salesforce.